Result: Major DRAMs to NNRTIs seen in the Prophylaxis plus ART Group (Group 1) were K103 N, Y181C, M230 L and L100IL and the minor DRAMs to NNRTIs seen was A98G.
Result: One minor drug resistance
Result: The most common HIV-1 drug resistance associated mutations seen with the NNRTIs were K103 N, M230 L and A98G.
Result: There were no major DRAMs to NNRTIs in this group though the minor drug resistance mutation, A98G, was seen in two of the patients.
Table: A98G
Detection of minority drug resistant mutations in Malawian HIV-1 subtype C-positive patients initiating and on first-line antiretroviral therapy.
PMID: 29977795
2018
African journal of laboratory medicine
Table: A98G
Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG-infected patients in Yaounde, Cameroon.
Method: Four subjects on ART also had viruses harboring the NNRTIs secondary mutations V179D, A98G, E138A, V179E, and F227L, including subject NA2CMR151 who had both A98G and the major NNRTI resistance mutation Y181C.
Method: Subject NA2CMR151 harbored viruses with both the Gag cleavage site mutations S373Q, T375G, I376V, G381S; the major NRTIs resistance mutations T69N, K70R, PMID: 28114955
2017
AIDS research and therapy
Table: A98G
Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial.
Result: The most frequently observed baseline etravirine RAMs were G190A (18/151), V90I (15/151), A98G (10/151), and K101E (9/151) (Supplementary Figure 1).
Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).
Result: One participant developed the NNRTI resistance substitution A98A/G, but this participant resuppressed HIV-1 RNA to <50 copies/mL while on study drugs.
Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations.
PMID: 26651266
2016
AIDS research and human retroviruses
Abstract: Subtype C- and F1-infected patients displayed the highest levels of reduced viral susceptibility at baseline, respectively 13.2% and 9.3%, mainly due to subtype- and geographic-dependent occurrence of RPV-RAMs E138A and A98G as natural polymorphisms.
Method: In addition, we defined a list of minor RPV-RAMs that have been observed in in vitro or in vivo selection studies and are included in one or more of clinically widely used genotypic resistance interpretation algorithms ANRS (V24), Rega (V9.1.0), and HIVdb (V7.0.1), encompassing V90I, A98G, L100I/V, K101H/Q/T, K103R/S, V106A/I, V108I, E138S, PMID: 27124362
2016
Journal of acquired immune deficiency syndromes (1999)
Introduction: However, in clinical trials individuals on an ETR containing regimen who experienced virological failure were infected with viruses that had a combination of RT mutations including V90I, A98G, L100I, K101E/P, V106I, V179D/F, Y181C/I/V, and G190A/S.
Ribonuclease H/DNA Polymerase HIV-1 Reverse Transcriptase Dual Inhibitor: Mechanistic Studies on the Allosteric Mode of Action of Isatin-Based Compound RMNC6.
Result: Furthermore, we tested RMNC6 against several mutants conferring resistance to NNRTIs such as K103N, Y181C and Y188L, and against the HIV-1 group O RT which shows natural resistance to NNRTIs due to the presence of the amino acid substitutions A98G, V179E and Y181C (S2 Appendix).
Short Communication: Population-Based Surveillance of HIV-1 Drug Resistance in Cameroonian Adults Initiating Antiretroviral Therapy According to the World Health Organization Guidelines.
PMID: 26602836
2016
AIDS research and human retroviruses
Abstract: Level of DRMs was low (3.77%) versus moderate (7.55%), respectively, following the WHO list (T69D, K103N) versus Stanford HIVdb (T69D, A98G, K103N, K238T), respectively.
HIV mutation literature information.
PMID: 
2018
Virology journal
Browser Board
Co-occurred Entities
Filtrator
ViMRT